Adar Poonawalla Serum commits 100-mn doses of vaccines for 15 pc stake in Biocon Biologics
Adar Poonawalla Serum commits 100-mn doses of vaccines for 15 pc stake in Biocon Biologics
Share:

Biocon Biologics Limited (BBL), a subsidiary of Biocon has announced a strategic alliance with Serum Institute Life Sciences (SILS). As per the agreement, the former will offer approximately 15 percent stake to the latter for access to 100 million doses of vaccines per annum for 15 years. Pursuant to the terms of the agreement, BBL would generate a committed revenue stream and related margins, commencing H2 of FY23.

Kiran Mazumdar-Shaw, Executive Chairperson, Biocon & Biocon Biologics, said, “This alliance will complement the strengths and resources of the two leading players in vaccines and biologics.'' Adar Poonawalla, CEO, Serum Institute of India, said, “We look forward to complementing each other’s capabilities and capacities in vaccines and biologics with the objective of addressing inequitable access, both in emerging and developed markets, for life-saving vaccines and biologics.”

In addition to vaccines, the strategic alliance will also develop antibodies targeting several infectious diseases like Dengue, HIV, etc. The two companies will enter Service Level Agreements (SLAs) for manufacturing and distribution of the vaccines and antibodies. These collaborations support Biocon Biologics’ intent of straddling on both infectious and non-communicable diseases in its quest to impact global health.

Ex-Tamil Nadu captain Sridharan Named Chairman of BCCI Junior Selection Committee

Chandrababu Naidu writes Jaganmohan Reddy to cancel jumbo sized TTD Trust board

CM Yogi distributed tool kits to 21,000 beneficiaries on Vishwakarma Jayanti

 

Join NewsTrack Whatsapp group
Related News